Literature DB >> 11489345

The NF-kappaB inhibitor diethyldithiocarbamate (DDTC) increases brain cell death in a transient middle cerebral artery occlusion model of ischemia.

W D Hill1, D C Hess, J E Carroll, C G Wakade, E F Howard, Q Chen, C Cheng, A Martin-Studdard, J L Waller, R A Beswick.   

Abstract

A transient ischemic middle cerebral artery occlusion model of stroke was used to examine the role of the transcription factor NF-kappaB in cell death as measured by DNA fragmentation and infarction volume. The left middle cerebral artery was occluded for either 30 min or 2 h in rats. One set of animals was pretreated with diethyldithiocarbamate (DDTC), an inhibitor of NF-kappaB, 30 min prior to reperfusion. The animals were reperfused and allowed to survive for 2 or 7 days. DNA fragmentation was assayed by in situ end labeling in the stroke core and penumbral regions. Specific cortical and subcortical regions were measured using quantitative image analysis. DNA fragmentation was seen only on the ischemic side of the brains in all cases. Overall, the DDTC-treated groups showed significantly increased DNA fragmentation within the ischemic side compared to the saline control groups. DDTC treatment also caused an increase in stroke volume based on triphenyl tetrazolium chloride staining. Electrophoretic mobility shift assays showed NF-kappaB activation peaking 15 min following reperfusion and that this activation was blocked by the DDTC treatment. This study suggests that the use of NF-kappaB inhibitors to block cell death following stroke needs to be carefully examined because global inhibitors may not promote neuronal survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489345     DOI: 10.1016/s0361-9230(01)00503-2

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  25 in total

Review 1.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

Review 2.  The inflammatory response in stroke.

Authors:  Qing Wang; Xian Nan Tang; Midori A Yenari
Journal:  J Neuroimmunol       Date:  2006-12-26       Impact factor: 3.478

Review 3.  Inflammatory responses in brain ischemia.

Authors:  Masahito Kawabori; Midori A Yenari
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

4.  Longitudinal assessment of imatinib's effect on the blood-brain barrier after ischemia/reperfusion injury with permeability MRI.

Authors:  Zamir Merali; Jackie Leung; D Mikulis; F Silver; Andrea Kassner
Journal:  Transl Stroke Res       Date:  2014-08-23       Impact factor: 6.829

Review 5.  Role of inflammation and its mediators in acute ischemic stroke.

Authors:  Rong Jin; Lin Liu; Shihao Zhang; Anil Nanda; Guohong Li
Journal:  J Cardiovasc Transl Res       Date:  2013-09-05       Impact factor: 4.132

Review 6.  Growing old with nuclear factor-kappaB.

Authors:  Charles Giardina; Andrea K Hubbard
Journal:  Cell Stress Chaperones       Date:  2002-04       Impact factor: 3.667

Review 7.  The effects of estrogen in ischemic stroke.

Authors:  Edward C Koellhoffer; Louise D McCullough
Journal:  Transl Stroke Res       Date:  2012-12-07       Impact factor: 6.829

8.  Post-stroke infections exacerbate ischemic brain injury in middle-aged rats: immunomodulation and neuroprotection by progesterone.

Authors:  S Yousuf; F Atif; I Sayeed; J Wang; D G Stein
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

9.  Inhibition of cerebral vascular inflammation by brain endothelium-targeted oligodeoxynucleotide complex.

Authors:  Jing Hu; Daniah Al-Waili; Aishlin Hassan; Guo-Chang Fan; Mei Xin; Jiukuan Hao
Journal:  Neuroscience       Date:  2016-04-27       Impact factor: 3.590

10.  NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells.

Authors:  Jiangbing Zhou; Hao Zhang; Peihua Gu; Jining Bai; Joseph B Margolick; Ying Zhang
Journal:  Breast Cancer Res Treat       Date:  2007-10-27       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.